Marumax

Tamsulosin Hydrochloride and Dutasteride, the active ingredient in Marumax, is an Alpha‑1 blocker and 5‑alpha‑reductase inhibitor presented as an oral tablet for oral use. It treats benign prostatic hyperplasia (BPH) in adult men by improving urinary flow and reducing prostate size.

GNH USA supplies Marumax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Marumax combines tamsulosin and dutasteride to address the pathophysiology of benign prostatic hyperplasia and related urinary symptoms.

- Benign prostatic hyperplasia: improves urinary flow and reduces prostate volume. - Lower urinary tract symptoms due to BPH: alleviates urgency, frequency and nocturia. - Risk of acute urinary retention: lowers the likelihood of sudden blockage requiring catheterisation.

Marumax may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Dizziness or light‑headedness. - Ejaculatory dysfunction or reduced libido. - Headache. - Nasal congestion.

Serious or Rare Side Effects: - Severe hypotension or syncope. - Priapism. - Allergic reactions such as rash, angioedema or anaphylaxis.

When prescribing Marumax, clinicians should consider several precautionary measures to ensure patient safety. - Monitor blood pressure: watch for orthostatic changes, especially after initiation. - Assess liver function: periodic tests are advisable due to dutasteride metabolism. - Avoid use in severe renal impairment without specialist advice. - Counsel patients on possible sexual side effects and impact on fertility. - Store at room temperature: keep in the original pack, protect from moisture.

Marumax can interact with other medicines; awareness of the interaction level helps guide therapy.

Major Interactions (Avoid): - Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise dutasteride concentrations. - Concomitant use of other alpha‑blockers with antihypertensives: risk of additive hypotension.

Moderate Interactions (Monitor Closely): - Warfarin: may increase bleeding tendency; monitor INR. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): monitor for blood pressure changes. - Diuretics: watch electrolytes and volume status.